Modifying the Host Range Properties of Retroviral Vectors

Journal of Gene Medicine

Volumn 1, Issue 5, 1999, Pages 300-311

  Russell, Stephen J ^a   Cosset, François Loïc ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITÉ DE LYON   (France)

Author keywords

Envelope glycoproteins; Retroviral vector; Targeting

Indexed keywords

LIGAND; VIRUS ENVELOPE PROTEIN; VIRUS RECEPTOR;

CHEMICAL STRUCTURE; CHEMISTRY; GENE TARGETING; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; PHYSIOLOGY; RETROVIRUS; REVIEW;

GENE TARGETING; GENE THERAPY; GENETIC VECTORS; HUMANS; LIGANDS; MODELS, MOLECULAR; RECEPTORS, VIRUS; RETROVIRIDAE; VIRAL ENVELOPE PROTEINS;

EID: 0033182002     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1521-2254(199909/10)1:5<300::AID-JGM59>3.0.CO;2-T     Document Type: Review

References (100)

1. Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990; 10: 4239-4242.
2. Poeschla E, Wong-Staal F, Looney D. Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat Med 1998; 4: 354-357.
3. Zufferey R, Nagy D, Mandel R, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotech 1997; 15: 871-875.
4. Hunter E. Viral entry and receptors. In Retroviruses, Coffin JM, Hughes SH, Varmus HE (eds). New York, USA: Cold Spring Harbor Laboratory Press, 1997; 71-120.
5. Hunter E, Swanstrom R. Retrovirus envelope glycoproteins. Curr Top Microbiol Immunol 1990; 157: 187-253.
6. Gliniak BC, Kozak SL, Jones RT, Kabat D. Disulfide bonding controls the processing of retroviral envelope glycoproteins. J Biol Chem 1991; 266: 22991-22997.
7. Pinter A, Kopelman R, Li Z, Kayman SC, Sanders DA. Localization of the labile disulfide bond between SU and TM of the murine leukemia virus envelope protein complex to a highly conserved CWLC motif in SU that resembles the active-site sequence of thiol-disulfide exchange enzymes. J Virol 1997; 71: 8073-8077.
8. Suomalainen M, Garoff H. Incorporation of homologous and heterologous proteins into the envelope of Moloney murine leukemia virus. J Virol 1994; 68: 4879-4889.
9. Ragheb JA, Anderson WF. pH-independent murine leukemia virus ecotropic envelope-mediated cell fusion: Implications for the role of the R peptide and p12E TM in viral entry. J Virol 1994; 68: 3220-3231.
10. Rein A, Mirro J, Haynes JG, Ernst SM, Nagashima K. Function of the cytoplasmic domain of a retroviral transmembrane protein: p15E-p2E cleavage activates the membrane fusion capability of the murine leukemia virus env protein. J Virol 1994; 68: 1773-1781.
11. Nussbaum O, Roop A, Anderson WF. Sequences determining the pH dependence of viral entry are distinct from the host range-determining region of the murine ecotropic and amphotropic retrovirus envelope proteins. J Virol 1993; 67: 7402-7405.
12. Schulz TF, Jameson BA, Lopalco L, Siccardi AG, Weiss RA, Moore JP. Conserved structural features in the interaction between retroviral surface and transmembrane glycoproteins? AIDS Res Hum Retroviruses 1992; 8: 1571-1580.
13. Battini JL, Danos O, Heard JM. Receptor-binding domain of murine leukemia virus envelope glycoproteins. J Virol 1995; 69: 713-719.
14. Battini JL, Heard JM, Danos O. Receptor choice determinants in the envelope glycoproteins of amphotropic, xenotropic, and polytropic murine leukemia viruses. J Virol 1992; 66: 1468-1475.
15. Morgan RA, Nussbaum O, Muenchau DD, Shu L, Couture L, Anderson WF. Analysis of the functional and host range-determining regions of the murine ecotropic and amphotropic retrovirus envelope proteins. J Virol 1993; 67: 4712-4721.
16. Ott D, Rein A. Basis for receptor specificity of non-ecotropic murine leukemia virus surface glycoprotein gp70. J Virol 1992; 66: 4632-4638.
17. MacKrell AJ, Soong NW, Curtis CM, Anderson WF. Identification of a subdomain in the Moloney murine leukemia virus envelope protein involved in receptor binding. J Virol 1996; 70: 1768-1774.
18. Bae Y, Kingsman SM, Kingsman AJ. Functional dissection of the Moloney murine leukemia virus envelope protein gp70. J Virol 1997; 71: 2092-2099.
19. Fass D, Davey RA, Hamson CA, Kim PS, Cunningham JM, Berger JM. Structure of a murine leukemia virus receptor-binding glycoprotein at 2.0 angstrom resolution. Science 1997; 277: 1662-1666.
20. Lavillette D, Ruggieri A, Russell SJ, Cosset F-L. Activation of a cell entry pathway common to C-type mammalian retroviruses by soluble envelope fragments. J Virol in press.
21. Lavillette D, Maurice M, Russell SJ, Cosset F-L. Functional cooperation between fusion mutants of murine leukemia virus (MLV) envelope glycoproteins: evidence for the implication of the MLV-SU amino-terminus at early post binding stage. Unpublished results.
22. Zavorotinskaya T, Albritton LM. Suppression of a fusion defect by second site mutations in the ecotropic murine leukemia virus surface protein. J Virol 1999; 73: 5034-5042.
23. Gray KD, Roth MJ. Mutational analysis of the envelope gene of Moloney murine leukemia virus. J Virol 1993; 67: 3489-3496.
24. Lavillette D, Maurice M, Roche C, Russell SJ, Sitbon M, Cosset F-L. A proline-rich motif downstream of the receptor binding domain modulates conformation and fusogenicity of murine retroviral envelopes. J Virol 1998; 72: 9955-9965.
25. Wu BW, Cannon PM, Gordon EM, Hall FL, Anderson WF. Characterization of the proline-rich region of murine leukemia virus envelope protein. J Virol 1998; 72: 5383-5391.
26. Fass D, Harrison SC, Kim PS. Retrovirus envelope domain at 1.7 Å resolution. Nat Struct Biol 1996; 3: 465-469.
27. Jones JS, Risser R. Cell fusion induced by the murine leukaemia virus envelope glycoprotein. J Virol 1993; 67: 67-74.
28. Zhu NL, Cannon PM, Chen D, Anderson WF. Mutational analysis of the fusion peptide of Moloney murine leukemia virus transmembrane protein p15E. J Virol 1998; 72: 1632-1639.
29. White JM. Membrane Fusion. Science 1992; 258: 917-924.
30. Bullough PA, Hughson FM, Skehel JJ, Wiley DC. Structure of influenza haemagglutinin at the pH of membrane fusion. Nature 1994; 371: 37-43.
31. Chen J, Lee KH, Steinhauer DA, Stevens DJ, Skehel JJ, Wiley DC. Structure of the hemagglutinin precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformation. Cell 1998; 95: 409-417.
32. Kobe B, Center RJ, Kemp BE, Poumbourios P. Crystal structure of human T cell leukemia virus type 1 gp21 ectodomain crystallized as a maltose-binding protein chimera reveals structural evolution of retroviral transmembrane proteins. Proc Natl Acad Sci U S A 1999; 96: 4319-4324.
33. Tailor CS, Kabat D. Variable regions A and B in the envelope glycoproteins of feline leukemia virus subgroup B and amphotropic murine leukemia virus interact with discrete receptor domains. J Virol 1997; 71: 9383-9391.
34. Davey RA, Zuo Y, Cunningham JM. Identification of a receptor-binding pocket on the envelope protein of friend murine leukemia virus. J Virol 1999; 73: 3758-3763.
35. Zavorotinskaya T, Albritton LM. Failure To cleave murine leukemia virus envelope protein does not preclude its incorporation in virions and productive virus-receptor interaction. J Virol 1999; 73: 5621-5629.
36. Zhao Y, Zhu L, Benedict CA, Chen D, Anderson WF, Cannon PM. Functional domains in the retroviral transmembrane protein. J Virol 1998; 72: 5392-5398.
37. Zhao Y, Lee S, Anderson WF. Functional interactions between monomers of the retroviral envelope protein complex. J Virrol 1997; 71: 6967-6972.
38. Rein A, Yang C, Haynes JA, Mirro J, Compans RW. Evidence for cooperation between murine leukemia virus Env molecules in mixed oligomers. J Virol 1998; 72: 3432-3435.
39. Heard JM, Rodrigues P, Salaün C. Une collaboration étroite et efficace: les enveloppes rétrovirales et leurs récepteurs cellulaires. Médecine/Science in press.
40. Siess DC, Kozak SL, Kabat D. Exceptional fusogenicity of chinese hamster ovary cells with murine retroviruses suggests roles for cellular factor(s) and receptor clusters in the membrane fusion process. J Virol 1996; 70: 3432-3439.
41. Battini JL, Rodrigues P, Müller R, Danos O, Heard JM. Receptor-binding properties of a purified fragment of the 4070A amphotropic murine leukemia virus envelope glycoprotein. J Virol 1996; 70: 4387-4393.
42. Wang H, Paul R, Burgeson R, Keene D, Kabat D. Plasma membrane receptors for ecotropic murine retroviruses require a limiting accessory factor. J Virol 1991; 65: 6468-6477.
43. Haywood A. Virus receptors: Binding, adhesion strengthening, and changes in viral structure. J Virol 1994; 68: 1-5.
44. Rodrigues P, Heard JM. Modulation of phosphate uptake and amphotropic murine leukemia virus entry by posttranslational modifications of PIT-2. J Virol 1999; 73: 3789-3799.
45. Kizhatil K, Albritton LM. Requirements for different components of the host cell cytoskeleton distinguish ecotropic murine leukemia virus entry via endocytosis from entry via surface fusion. J Virol 1997; 71: 7145-7156.
46. Klasse PJ, Bron R, Marsh M. Mechanism of enveloped virus entry into animal cells. Adv Drug Delivery Reviews 1998; 34: 65-91.
47. Goud B, Legrain P, Buttin G. Antibody-mediated binding of a murine ecotropic Moloney retroviral vector to human cells allows internalization but not the establishment of the proviral state. Virology 1988; 163: 251-254.
48. Roux P, Jeanteur P, Piechaczyk M. A versatile approach to the targetting of specific cell types by retroviruses. Proc Natl Acad Sci U S A 1989; 86: 9079-9083.
49. Etienne-Julan M, Roux P, Carillo S, Jeanteur P, Piechaczyk M. The efficiency of cell targetting by recombinant retroviruses depends on the nature of the receptor and the composition of the artificial cell-virus linker. J Gen Virol 1992; 73: 3251-3255.
50. Snitkovsky S, Young JA. Cell-specific viral targeting mediated by a soluble retroviral receptor-ligand fusion protein. Proc Natl Acad Sci U S A 1998; 95: 7063-7068.
51. Valsesia-Wittmann S, Drynda A, Deleage G et al. Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors. J Virol 1994; 68: 4609-4619.
52. Hall FL, Gordon EM, Wu L et al. Targeting retroviral vectors to vascular lesions by genetic engineering of the MoMLV gp70 envelope protein. Hum Gene Ther 1997; 8: 2183-2192.
53. Russell SJ, Hawkins RE, Winter G. Retroviral vectors displaying functional antibody fragments. Nucleic Acids Res 1993; 21: 1081-1085.
54. Kayman SC, Park H, Saxon M, Pinter A. The hypervariable domain of the murine leukemia virus surface protein tolerates large insertions and deletions, enabling development of a retroviral particle display system. J Virol 1999; 73: 1802-1808.
55. Nilson BHK, Morling FJ, Cosset F-L, Russell SJ. Targeting of retroviral vectors through protease-substrate interactions. Gene Ther 1996; 3: 280-286.
56. Chu THT, Martinez I, Sheay WC, Dornburg R. Cell targeting with retroviral vector particles containing antibody-envelope fusion proteins. Gene Ther 1994; 1: 292-299.
57. Chu THT, Dornburg R. Retroviral vector particles displaying the antigen-binding site of an antibody enable cell-type-specific gene transfer. J Virol 1995; 69: 2659-2663.
58. Han X, Kasahara N, Kan YW. Ligand-directed retroviral targeting of human breast cancer cells. Proc Natl Acad Sci U S A 1995; 92: 9747-9751.
59. Jiang A, Chu TH, Nocken F, Cichutek K, Dornburg R. Cell-type-specific gene transfer into human cells with retroviral vectors that display single-chain antibodies. J Virol 1998; 72: 10148-10156.
60. Kasahara N, Dozy AM, Kan YW. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 1994; 266: 1373-1376.
61. Matano T, Odawara T, Iwamoto A, Yoshikura H. Targeted infection of a retrovirus bearing a CD4-Env chimera into human cells expressing human immunodeficiency virus type 1. J Gen Virol 1995; 76: 3165-3169.
62. Nguyen T, Pages J-C, Farge D, Briand P, Weber A. Amphotropic retroviral vectors displaying hepatocyte growth factor-envelope fusion proteins improve transduction efficiency of primary hepatocytes. Hum Gene Ther 1998; 9: 2469-2479.
63. Benedict CA, Tun RY, Rubinstein DB, Guillaume T, Cannon PM, Anderson WF. Targeting retroviral vectors to CD34-expressing cells: binding to CD34 does not catalyze virus-cell fusion. Hum Gene Ther 1999; 10: 545-557.
64. Cosset F-L, Morling FJ, Takeuchi Y, Weiss RA, Collins MKL, Russell SJ. Retroviral retargeting by envelopes expressing an N-terminal binding domain. J Virol 1995a; 69: 6314-6322.
65. Ager S, Nilson BHK, Morling FJ, Peng KW, Cosset F-L, Russell SJ. Retroviral display of antibody fragments; interdomain spacing strongly influences vector infectivity. Hum Gene Ther 1996; 7: 2157-2164.
66. Valsesia-Wittmann S, Morling FJ, Nilson BHK, Takeuchi Y, Russell SJ, Cosset F-L. Improvement of retroviral retargeting by using amino acid spacers between an additional binding domain and the N terminus of Moloney murine leukemia virus SU. J Virol 1996; 70: 2059-2064.
67. Valsesia-Wittmann S, Morling FJ, Hatziioannou T, Russell SJ, Cosset F-L Receptor co-operation in retrovirus entry: recruitment of an auxilliary entry mechanism after retargeted binding. EMBO J 1997; 16: 1214-1223.
68. Zhao Y, Zhu L, Lee S et al. Identification of the block in targeted retroviral-mediated gene transfer. Proc Natl Acad Sci U S A 1999; 96: 4005-4010.
69. Fielding AK, Maurice M, Morling FJ, Cosset F-L, Russell SJ. Inverse targeting of retroviral vectors: selective gene transfer in a mixed population of hematopoietic and nonhematopoietic cells. Blood 1998; 91: 1802-1809.
70. Lee S, Zhao Y, Anderson WF. Receptor-mediated moloney murine leukemia virus entry can occur independently of the clathrin-coated-pit-mediated endocytic pathway. J Virol 1999; 73: 5994-6005.
71. Hatziioannou T, Valsesia-Wittmann S, Russell S, Cosset F-L. Incorporation of fowl plague virus hemagglutinin into murine leukemia virus particles and analysis of the infectivity of the pseudotyped retroviruses. J Virol 1998; 72: 5313-5317.
72. Konishi H, Ochiya T, Chester KA et al. Targeting strategy for gene delivery to carcinoembryonic antigen-producing cancer cells by retrovirus displaying a single-chain variable fragment antibody. Hum Gene Ther 1998; 9: 235-248.
73. Marin M, Noël D, Valsesia-Wittmann S et al. Targeted infection of human cells via MHC class I molecules by MoMuLV-derived viruses displaying single-chain antibody fragment-envelope fusion proteins. J Virol 1996; 70: 2957-2962.
74. Martin F, Kupsch J, Takeuchi Y, Russell S, Cosset F-L, Collins M. Retroviral vector targeting to melanoma cells by single-chain antibody incorporation in envelope. Hum Gene Ther 1998; 9: 737-746.
75. Somia NV, Zoppé M, Verma IM. Generation of targeted retroviral vectors by using single-chain variable fragment: an approach to in vivo gene delivery. Proc Natl Acad cid U S A 1995; 92: 7570-7574.
76. Yajima T, Kanda T, Yoshiike K, Kitamura Y. Retroviral vector targeting human cells via c-Kit-stem cell factor interaction. Hum Gene Ther 1998; 10: 779-787.
77. Cosset F-L Russell SJ. Targeting retrovirus entry. Gene Ther 1996; 3: 946-956.
78. Gautier R, Jiang A, Rousseau V, Dornburg R, Jaffredo T. Avian Spleen Necrosis Virus is non-infectious for human cells. Unpublished results.
79. Weiss RA, Tailor CS. Retrovirus receptors. Cell 1995; 82: 531-533.
80. Gilbert JM, Hernandez LD, Balliet JW, Bates P, White JM. Receptor-induced conformational changes in the subgroup A avian leukosis and sarcoma virus envelope glycoprotein. J Virol 1995; 69: 7401-7415.
81. Sullivan N, Sun Y, Sattentau Q et al. CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization. J Virol 1998; 72: 4694-4703.
82. Reeves JD, Schulz TF. The CD4-independent tropism of human immunodeficiency virus type 2 involves several regions of the envelope protein and correlates with a reduced activation threshold for envelope-mediated fusion. J Virol 1997; 71: 1453-1465.
83. Chadwick MP, Morling FJ, Cosset F-L, Russell SJ. Modification of retroviral tropism by display of IGF-I. J Mol Biol 1999; 285: 485-494.
84. Maurice M, Mazur S, Bullough FJ et al. Efficient gene delivery to quiescent IL2-dependent cells by murine leukemia virus-derived vectors harboring IL2 chimeric envelopes glycoproteins. Blood 1999; 94: 401-410.
85. Wiley DC, Skehel JJ. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu Rev Biochem 1987; 56: 365-394.
86. Carr C, Kim P. A spring-loaded mechanism for the conformational change of influenza hemagglutinin. Cell 1993; 73: 823-832.
87. Nobusawa E, Nakajima K. Amino acid substitution at position 226 of the hemagglutinin molecule of influenza (H1N1) virus affects receptor binding activity but not fusion activity. Virology 1987; 167: 8-14.
88. Hatziioannou T, Delahaye E, Martin F, Russell SJ, Cosset F-L. Retroviral display of functional binding domains fused to the amino-terminus of influenza haemagglutinin. Hum Gene Ther 1999; 10: 1533-1544.
89. Patterson SM, Swainsbury R, Routledge EG. Antigen-specific membrane fusion mediated by the haemagglutinin protein of influenza A virus: separation of attachment and fusion functions on different molecules. Gene Ther 1999; 6: 694-702.
90. Mukherjee S, Ghosh RN, Maxfield FR. Endocytosis. Physiol Rev 1997; 77: 759-803.
91. Schwartz AL. Receptor cell biology: receptor-mediated endocytosis. Pediatr Res 1995; 38: 835-843.
92. Burns JC, Friedmann T, Driever W, Burrascano M, Yee JK. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci U S A 1993; 90: 8033-8037.
93. Miletic H, Bruns M, Tsiakas K et al. Retroviral vectors pseudotyped with lymphocytic choriomeningitis virus. J Virol 1999; 73: 6114-6116.
94. Peng KW, Morling F.J, Cosset F-L, Murphy G, Russell SJ. A gene delivery system activatable by disease-associated matrix metalloproteinases. Hum Gene Ther 1997; 8: 729-738.
95. Peng KW, Morling FJ, Cosset F-L, Russell SJ. A retroviral gene delivery system activatable by plasmin. Tumor Targeting 1998; 3: 112-120.
96. Morling FJ, Peng K-W, Cosset F-L, Russell SJ. Masking of retroviral envelope functions by oligomerizing peptide adaptors. Virology 1997; 234: 51-61.
97. Peng K-W, Vile RG, Cosset F-L, Russell SJ. Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors. Gene Ther 1999; 6: 1552-1557.
98. Martin F, Neil S, Kupsch J, Maurice M, Cosset F-L, Collins M. Retrovirus targeting by tropism restriction to melanoma cells. J Virol 1999; 73: 6923-6929.
99. Buchholz CJ, Peng K-W, Morling FJ, Zhang J, Cosset F-L, Russell SJ. In vivo selection of protease cleavage sites from retrovirus display libraries. Nat Biotech 1998; 16: 951-954.
100. Boerger AL, Snitkovsky S, Young JAT. Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types. Proc Natl Acad Sci U S A 1999; 96: 9867-9872.